JPH09504274A - 人工表面および血管面の血栓を予防する酸化窒素付加物の利用 - Google Patents
人工表面および血管面の血栓を予防する酸化窒素付加物の利用Info
- Publication number
- JPH09504274A JPH09504274A JP7509234A JP50923495A JPH09504274A JP H09504274 A JPH09504274 A JP H09504274A JP 7509234 A JP7509234 A JP 7509234A JP 50923495 A JP50923495 A JP 50923495A JP H09504274 A JPH09504274 A JP H09504274A
- Authority
- JP
- Japan
- Prior art keywords
- nitric oxide
- artificial
- nitroso
- blood
- thrombus formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.人工表面を酸化窒素付加物に接触させることよりなる血液と接触する前記人 工表面での血小板の付着あるいは血栓形成を妨げる一つの方法。 2.請求の範囲第1項記載の方法であって、前記人工表面はカテーテル、人工心 臓弁、人工心肺支援装置、合成血管移植片、血液透析膜、血液導管、血液貯蔵袋 、動静脈バイパス、あるい人工心臓よりなることを特徴とする方法。 3.請求の範囲第1項記載の方法であって、ここで前記酸化窒素付加物がニトロ グリセリン、ニトロプルシドナトリウム、S−ニトロソタンパク質、S−ニトロ ソチオール、長炭素鎖親脂質S−ニトロソチオール、S−ニトロソ−ジチオール 、鉄ニトロシル化合物、チオニトレート、チオニトライト、シドノニマイン、フ ロクサン、有機ニトレートあるいはニトロソ化アミノ酸を含むことを特徴とする 方法。 4.請求の範囲第3項記載の方法であって、前記S−ニトロソ−タンパク質がS −ニトロソ−アルブミン、S−ニトロソ−TPAあるいは受容体へのニトロソ化 抗体であり、正常あるいは損傷動脈壁に露出されることを特徴とする方法。 5.人工表面での血小板付着あるいは血栓形成を妨げる一つの方法であって、抗 血栓形成化合物と併用して酸化窒素付加物で人工表面を接触させることよりなる 方法。 6.請求の範囲第5項記載の方法であって、前記抗血栓形成化合物がヘパリン、 ヒルジンおよびその類似体、ウォーフェリン、アスピリン、インドメタシン、ジ ピリダモル、あるいはス ルフィンピラゾン、フェノチアジン、RGDペプチドおよびRGDペプチド擬態 物、血小板をブロックする薬剤、糖タンパク質IIb−IIIa受容体、チクロ ピジンあるいはクロピドグレルを含むことを特徴とする方法。 7.損傷血管面で血栓形成を妨げる一つの方法であって、酸化窒素付加物の治療 上有効な量を直接損傷表面に適用することよりなることを特徴とする方法。 8.請求の範囲第7項記載の方法であって、ここで前記酸化窒素付加物がニトロ グリセリン、ニトロプルシドナトリウム、S−ニトロソタンパク質、S−ニトロ ソチオール、長炭素鎖親脂質S−ニトロソチオール、S−ニトロソ−ジチオール 、鉄ニトロシル化合物、チオニトレート、チオニトライト、シドノニミン、フロ クサン、有機ニトレートあるいはニトロソ化アミノ酸を含むことを特徴とする方 法。 9.請求の範囲第7項記載の方法であって、ここで前記酸化窒素付加物が動脈内 あるいは静脈内カテーテルを用いて適用されることを特徴とする方法。 10.請求の範囲第9項記載の方法であって、ここで前記動物がヒトであること を特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12333193A | 1993-09-17 | 1993-09-17 | |
US08/123,331 | 1993-09-17 | ||
PCT/US1994/010027 WO1995007691A1 (en) | 1993-09-17 | 1994-09-08 | Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09504274A true JPH09504274A (ja) | 1997-04-28 |
Family
ID=22408037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7509234A Ceased JPH09504274A (ja) | 1993-09-17 | 1994-09-08 | 人工表面および血管面の血栓を予防する酸化窒素付加物の利用 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP1393723A3 (ja) |
JP (1) | JPH09504274A (ja) |
AU (1) | AU698748B2 (ja) |
CA (1) | CA2170772C (ja) |
DE (1) | DE69433478T2 (ja) |
WO (1) | WO1995007691A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5973011A (en) * | 1994-03-30 | 1999-10-26 | Isis Pharma Gmbh | Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction |
GB9423868D0 (en) * | 1994-11-25 | 1995-01-11 | Wellcome Found | Compounds for use in medicine |
US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
US5665077A (en) * | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6911427B1 (en) | 1995-09-15 | 2005-06-28 | Duke University | No-modified hemoglobins and uses therefore |
US6855691B1 (en) | 1995-09-15 | 2005-02-15 | Duke University | Methods for producing and using S-nitrosohemoglobins |
US6197745B1 (en) | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5797887A (en) * | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
NZ334389A (en) * | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
FR2757864B1 (fr) * | 1996-12-30 | 1999-03-19 | Centre Nat Rech Scient | Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique |
AT405135B (de) * | 1997-01-17 | 1999-05-25 | Immuno Ag | Präparation umfassend thiolgruppen-hältige proteine |
ATE238279T1 (de) | 1998-02-27 | 2003-05-15 | Sankyo Co | Zyklische aminoverbindungen |
KR20010083057A (ko) * | 1998-06-19 | 2001-08-31 | 추후제출 | 항-감염 및 피임성을 갖는 의료 장치 |
US6207855B1 (en) | 1998-06-23 | 2001-03-27 | Duke University Medical Center | Stable no-delivering compounds |
ES2147162B1 (es) * | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
US6838050B1 (en) | 1999-06-04 | 2005-01-04 | Oxibio, Inc. | Methods and devices for providing anti-infective activity to a medical device |
DE60138683D1 (de) * | 2000-01-25 | 2009-06-25 | Edwards Lifesciences Corp | Bioaktive beschichtungen zur vermeidung von gewebewachstum auf künstlichen herzklappen |
AU2001238518B2 (en) * | 2000-04-04 | 2006-09-07 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
SE523216C2 (sv) * | 2001-07-27 | 2004-04-06 | Zoucas Kirurgkonsult Ab | Heparinstent |
JP5274248B2 (ja) | 2005-05-27 | 2013-08-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子 |
US7744928B2 (en) | 2006-04-14 | 2010-06-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treatment of lesioned sites of body vessels |
US9259535B2 (en) | 2006-06-22 | 2016-02-16 | Excelsior Medical Corporation | Antiseptic cap equipped syringe |
US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
EP1939179A1 (en) | 2006-12-28 | 2008-07-02 | Lacer, S.A. | Stable S-nitrosothiols, method of synthesis and use |
US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
AU2010249558A1 (en) | 2009-05-20 | 2011-12-08 | Arsenal Medical, Inc. | Medical implant |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
EP2467127B1 (en) | 2009-08-21 | 2023-08-02 | Novan, Inc. | Topical gels |
BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
US8372133B2 (en) | 2009-10-05 | 2013-02-12 | 480 Biomedical, Inc. | Polymeric implant delivery system |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
EP2731658B1 (en) | 2011-07-12 | 2020-04-01 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into trans-dermal catheter |
PL2668947T3 (pl) * | 2012-05-31 | 2017-06-30 | G. Pohl-Boskamp Gmbh & Co. Kg | Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna |
CA2982456A1 (en) | 2015-05-08 | 2016-11-17 | Icu Medical, Inc. | Medical connectors configured to receive emitters of therapeutic agents |
SI3525865T1 (sl) | 2016-10-14 | 2023-01-31 | Icu Medical, Inc. | Razkuževalni pokrovčki za medicinske konektorje |
WO2018204206A2 (en) | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
CA3118905A1 (en) | 2018-11-21 | 2020-05-28 | Icu Medical, Inc. | Antimicrobial device comprising a cap with ring and insert |
CA3204371A1 (en) | 2020-12-07 | 2022-06-16 | Icu Medical, Inc. | Peritoneal dialysis caps, systems and methods |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4734097A (en) * | 1981-09-25 | 1988-03-29 | Nippon Oil Company, Ltd. | Medical material of polyvinyl alcohol and process of making |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US5025001A (en) * | 1988-06-15 | 1991-06-18 | Brigham And Women's Hospital | S-nitroso derivatives of ACE inhibitors and the use thereof |
US5002964A (en) * | 1988-06-15 | 1991-03-26 | Brigham & Women's Hospital | S-nitrosocaptopril compounds and the use thereof |
US4900719A (en) * | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5004461A (en) * | 1989-03-23 | 1991-04-02 | Wilson Joseph E | Methods for rendering plastics thromboresistant and product |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
EP1025853A3 (en) * | 1991-11-14 | 2000-11-08 | Brigham And Women's Hospital | Pharmaceutical composition containing S-nitroso-heme proteins and use thereof |
CA2106105C (en) * | 1993-09-14 | 2008-03-18 | Larry K. Keefer | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
-
1994
- 1994-09-08 DE DE69433478T patent/DE69433478T2/de not_active Expired - Fee Related
- 1994-09-08 EP EP03026675A patent/EP1393723A3/en not_active Withdrawn
- 1994-09-08 JP JP7509234A patent/JPH09504274A/ja not_active Ceased
- 1994-09-08 WO PCT/US1994/010027 patent/WO1995007691A1/en active IP Right Grant
- 1994-09-08 AU AU78312/94A patent/AU698748B2/en not_active Ceased
- 1994-09-08 CA CA002170772A patent/CA2170772C/en not_active Expired - Fee Related
- 1994-09-08 EP EP94929143A patent/EP0724436B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1393723A2 (en) | 2004-03-03 |
EP0724436A4 (en) | 1999-09-01 |
DE69433478D1 (de) | 2004-02-12 |
EP1393723A3 (en) | 2004-10-20 |
EP0724436A1 (en) | 1996-08-07 |
EP0724436B1 (en) | 2004-01-07 |
DE69433478T2 (de) | 2004-11-25 |
AU698748B2 (en) | 1998-11-05 |
AU7831294A (en) | 1995-04-03 |
CA2170772C (en) | 2005-03-29 |
CA2170772A1 (en) | 1995-03-23 |
WO1995007691A1 (en) | 1995-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09504274A (ja) | 人工表面および血管面の血栓を予防する酸化窒素付加物の利用 | |
JP2758953B2 (ja) | 血小板依存性動脈血栓症の予防方法 | |
Bidstrup et al. | Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) | |
Fuster et al. | Noninvasive radioisotopic technique for detection of platelet deposition in coronary artery bypass grafts in dogs and its reduction with platelet inhibitors. | |
Harker et al. | Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. | |
US20040255956A1 (en) | Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs | |
EA004047B1 (ru) | Применение глицинбетаина в качестве антитромботического средства | |
US4909799A (en) | Methods for preventing thrombosis; and surgical implant having reduced platelet deposition characteristics | |
AU2006201961A1 (en) | Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium | |
EP0211629A1 (en) | Irrigational hemostatic solution | |
JP4212114B2 (ja) | 抗血栓剤としてのp1,p4―ジチオ―p2―p3―モノクロロメチレン5’,5’’’―ジアデノシン p1,p4―テトラホスフェート | |
KR20010110788A (ko) | 저분자량 트롬빈 억제제 및 이의 프로드러그를 포함하는제약학적 제제 | |
JPH11505138A (ja) | ヘパリンのバイオ特異的除去のための装置および方法 | |
WO1996016645A1 (en) | Use of nitric oxide donors in medicine | |
US5523292A (en) | Method of preventing restenosis following coronary angioplasty | |
JPH07500585A (ja) | 造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用 | |
Ingerman-Wojenski et al. | Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719 | |
Badimon et al. | Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist | |
Nuutinen et al. | The effect of dipyridamole on the thrombocyte count and bleeding tendency in open-heart surgery | |
Friedman et al. | Polytetrafluoroethylene grafts in the peripheral venous circulation of rabbits | |
Janicki et al. | Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients | |
US6231847B1 (en) | Method of treating vascular proliferative responses | |
Escudero-Vela et al. | Prevention of the formation of arterial thrombi using different antiplatelet drugs: experimental study in dogs | |
He et al. | Comparison of secondary ischemic tolerance between pedicled and free island buttock skin flaps in the pig | |
Spallone et al. | Effect of antithrombotic agents after carotid endarterectomy in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050207 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060411 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060426 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060426 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060516 Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060710 Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060710 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061127 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070320 |